Non-interventional study to assess the safety profile of idelalisib in patients with refractory follicular lymphoma (FL)

First published 27/06/2017

Last updated 02/07/2024

EU PAS number:

EUPAS19618

Study

Finalised

Documents

Study protocol

Initial protocol

GS-EU-313-4172 Protocol Final V1.1 13Jun2017

English (679.41 KB - PDF) View document

Updated protocol

GS-EU-313-4172-16.1.1-appendix-protocol Amendment 4.1_f-redact

First published: 22/02/2024

English (6.55 MB - PDF) View document

Study results

GS-EU-313-4172_Final Report Abstract_v2.0_01September2022_Approved_f-redact

English (832.36 KB - PDF) View document

Study report

Other information

Secondary tabs